F
Ford Motor Company
F lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
NCI
Neo-Concept International Group Holdings Limited
There isn't enough reported data to score NCI yet.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
NCI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
NCI's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
NCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $4.21 | -18% |
| Current | 7.9x | $5.12 | — |
| Fair | 13x | $8.38 | +64% |
| Expensive | 107x | $69.87 | +1265% |
Historical ranges are pointers, not guarantees.
NCI's PE is 7.8x, but its earnings don't support one, so it isn't a reliable read right now.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect F's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NCI Forward outlook
There aren't enough analyst estimates for NCI to show an outlook.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has swung to a loss: it lost $1.97 per share over the past year, after a profit the year before.
NCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.65 | -96% |
| Q4 2024 | $16.71 | +64% |
| Q4 2023 | $10.19 | -64% |
| Q4 2022 | $28.08 | +128% |
NCI has the edge over F in the latest year-over-year earnings comparison.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
NCI has the stronger quarterly revenue trend. Revenue is down 2% for F versus up 77% for NCI.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F's operating margin was 2.9% last quarter, about level with the same quarter a year ago.
NCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $17.5M | -42% |
| Q4 2024 | $30M | +35% |
| Q4 2023 | $22.2M | +125% |
| Q4 2022 | $9.9M | -7.4% |
| Q3 2022 | $9.9M | -7.4% |
| Q2 2022 | $12.2M | +164% |
| Q1 2022 | $12.2M | +164% |
NCI's revenue is growing: $17M last quarter, up 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1.3% | -1.6 points |
| Q4 2024 | 4.9% | -2.5 points |
| Q4 2023 | 5.2% | -2.3 points |
| Q4 2022 | 3% | -0.4 points |
| Q3 2022 | 3% | -0.4 points |
| Q2 2022 | 7.5% | +9 points |
| Q1 2022 | 7.5% | +9 points |
| Q4 2021 | 3.3% | N/A |
NCI's operating margin was 1.3% last quarter, down 1.6 points from the same quarter a year ago.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F has the stronger cash trend. Its trailing FCF is down 42% versus its history, compared with NCI at down 156%.
NCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $2.2M | +$2.7M |
| Q4 2024 | -$473.3K | +$6M |
| Q4 2023 | -$6.4M | -$1.6M |
| Q4 2022 | -$4.8M | -883% |
| Q3 2022 | -$4.8M | -883% |
| Q2 2022 | $2.1M | +5597% |
| Q1 2022 | $2.1M | +5597% |
NCI's free cash flow was −$9M over the past year, against −$45,684 the year before.
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has the edge over NCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
NCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +2.2K shares |
| 1 year | +13% | +7.3K shares |
NCI has 63,500 diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has more cash than debt.
NCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.4x | Very low |
| Q4 2024 | 1.3x | Healthy |
| Q4 2023 | 2.7x | Moderate |
| Q4 2022 | 4.0x | Elevated |
| Q2 2022 | 1.4x | Healthy |
| Q4 2021 | 5.8x | High |
NCI's net debt is less than a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
NCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 1.9 | Oversold |
NCI's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
NCI PE vs Consumer Cyclical Sector
| Metric | NCI | Sector median | Relative |
|---|---|---|---|
| PE | 7.9x | 18x | 56% below |
| PE % | 34 | 24 | 10 pts above |
NCI is trading at 7.8x earnings, a 56% discount to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
NCI has stronger trend alignment. F is above 0 of 5 weekly averages versus NCI above 0 of 4.
NCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 74% below |
| 20 week MA | $67.8 | 92% below |
| 50 week MA | $117.5 | 96% below |
| 100 week MA | $125.3 | 96% below |
NCI is in a downtrend: it's below all four of its weekly moving averages, and 96% below its 100-week average.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F has the edge over NCI on returns for 2026, with the stronger performance.
NCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $601.6 | $167.0 | -72% |
| 2025 | $167.0 | $78.1 | -53% |
| 2026 YTD | $78.1 | $5.12 | -93% |
NCI has finished every year since 2024 lower, and it's down 93% so far in 2026.